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Summary
Congenital nephrotic syndrome of the Finnish type
(NPHS1) is an autosomal recessive disorder that is
caused by mutations in the recently discovered nephrin
gene, NPHS1 (AF035835). The disease, which belongs
to the Finnish disease heritage, exists predominantly in
Finland, but many cases have been observed elsewhere
in Europe andNorth America. The nephrin gene consists
of 29 exons spanning 26 kb in the chromosomal region
19q13.1. In the present study, the genomic structure of
the nephrin gene was analyzed, and 35 NPHS1 patients
were screened for the presence of mutations in the gene.
A total of 32 novel mutations, including deletions; in-
sertions; nonsense, missense, and splicingmutations; and
two common polymorphisms were found. Only two
Swedish and four Finnish patients had the typical Finn-
ish mutations: a 2-bp deletion in exon 2 (Finmajor) or a
nonsense mutation in exon 26 (Finminor). In seven cases,
no mutations were found in the coding region of the
NPHS1 gene or in the immediate 5′-flanking region.
These patients may have mutations elsewhere in the pro-
moter, in intron areas, or in a gene encoding another
protein that interacts with nephrin.
Introduction
Congenital nephrotic syndrome of the Finnish type
(CNF, NPHS1; MIM 256300) is an autosomal recessive
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disease characterized by massive proteinuria, detectable
in utero, a large placenta (125% of the newborn’s
weight), and marked edema (Hallman et al. 1956). The
onset of nephrotic syndrome usually occurs within the
first days of life and always before 3 mo of age. NPHS1
previously resulted in death before age 2 years, but it
can now be treated by renal transplantation, without the
development of extrarenal symptoms (Holmberg 1991,
1995).
We previously localized the NPHS1 gene to chro-
mosome 19q13.1 (Kestila¨ et al. 1994; Ma¨nnikko¨ et al.
1995) and recently identified the actual gene (Kestila¨ et
al. 1998). The NPHS1 gene is 26 kb in size and contains
29 exons. The gene product, termed “nephrin,” is a ten-
tative membrane protein that is not notably expressed
in extrarenal tissues. In the kidney, nephrin expression
is observed only in visceral epithelial cells of the glo-
meruli, as determined by in situ hybridization, indicating
its importance for the development or maintenance of
the glomerular filtration barrier. Four different muta-
tions have been reported in numerous Finnish and two
North American families (Kestila¨ et al. 1998). Most
(78%) Finnish NPHS1 chromosomes and one North
American patient had a 2-bp deletion in exon 2 (Finmajor)
that caused a frameshift and a translation stop at the
end of exon 2. A nonsense mutation in exon 26 (Finminor)
was observed in 16% of Finnish NPHS1 chromosomes.
One American patient was a heterozygote for the Finmajor
mutation, carrying a single base insertion in exon 24 of
the other allele. Another North American patient was a
homozygote for a 2-bp insertion in exon 10.
NPHS1 belongs to the Finnish disease heritage, which
refers to enrichment of a disease in the isolated Finnish
population (Nevanlinna 1972). Almost half of the
known NPHS1 cases worldwide have been diagnosed in
Finland (Norio et al. 1966). The incidence of NPHS1 is
∼1:10,000 newborns in Finland (Huttunen 1976), but
the incidence is considerably lower in other countries.
For example, Albright et al. (1990) estimated an inci-
dence of ∼1:50,000 in North America. Cases of NPHS1
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Table 2
Missense Mutations in NPHS1 Gene Found in Congenital Nephrotic Syndrome Patients
Exon
Nucleotide
Change
Mutation
Code
Effect on
Protein Patients Patient Origin
2 nt191(GrC) W64S Trp64rSer 19 Finland
4 nt512(TrA) I171N Ile171rAsn 2 Turkey
4 nt518(TrA) I173N Ile173rAsn 14 France
7 nt808(GrT) G270C Gly270rCys 22 England
9 nt1048(TrC) S350P Ser350rPro 14 France
9 nt1096(ArC) S366R Ser366rArg 1, 11 Croatia, North America
9 nt1099(CrT) R367C Arg367rCys 21a France
9 nt1102 (CrT) P368S Pro368rSer 9b Netherlands
9 nt1126 (CrG) L376V Leu376rVal 9b Netherlands
10 nt1223(GrA) R408Qc Arg408rGln 18a, 23 28d Finland, North America
11 nt1384(GrA) C465Y Cys465rTyr 18a Finland
12 nt1583(GrT) C528F Cys528rPhe 15 France
14 nt1829(TrA) L610Q Leu610rGln 15 France
14 nt1868(GrT) C623F Cys623rPhe 23 North America
16 nt2171(CrG) S724C Ser724rCys 21a France
17 nt2227(CrT) R743C Arg743rCys 20 Finland
18 nt2404(CrT) R802W Arg802rTrp 17 Netherlands
18 nt2405 (GrC) R802P Arg802rPro 12 North America
18 nt2417(CrA) A806D Ala806rAsp 3 Morocco
18 nt2491(CrT) R831C Arg831rCys 25d North America
27 nt3418(CrT) R1140C Arg1140rCys 21a France
a Three heterozygous mutations found.
b Patient is homozygous for P368S and heterozygous for L376V.
c Mutation found also in 4/30 controls as a heterozygous change.
d Mutation found only in one allele.
have also been reported in several other countries (Ma-
han et al. 1984; Mauch et al. 1994). Linkage to the
NPHS1 locus has been shown by Ma¨nnikko¨ et al. (1996)
and Fuchshuber et al. (1996) in non-Finnish NPHS1
cases, indicating a more general involvement of the ne-
phrin gene in hereditary nephrotic syndromes. In the
present article, we describe in detail the structure of the
human NPHS1 gene, primers for amplification of its
exon regions, and several novel mutations in the gene
in CNF patients from Europe, North America, and
North Africa.
Subjects, Material, and Methods
Structure of the NPHS1 Gene
Cosmid clone R33502 (AC002133) from chromoso-
mal region 19q13.1 containing the NPHS1 gene encod-
ing nephrin was sequenced in its entirety. Potential cod-
ing areas were searched with several exon-prediction
programs (e.g., GRAILII [Uberbacher and Mural 1991],
FEXH, HEXON, FGENEH [Solovyev et al. 1994], and
GENSCAN [Burge and Karlin 1997]), and primers were
designed to create cDNAs from fetal kidney mRNA by
reverse transcription PCR. A cDNA of 4.3 kb was se-
quenced and compared with the genomic sequence to
obtain the gene structure. The SIGNAL SCAN program
(Prestridge 1991) was used to analyze the promoter area.
Patients and Control Material
Genomic DNA was extracted according to standard
laboratory protocol (Vandenplas et al. 1984) from peri-
pheral blood leukocytes from 30 non-Finnish controls,
10 Finnish controls, and 35 NPHS1 patients and their
parents from North America, Europe, and North Africa.
The diagnosis of NPHS1 was made on the basis of a
large placenta and severe proteinuria at birth, with ne-
phrotic syndrome appearing during the first weeks of
life, and, whenever possible, a renal histology compat-
ible with NPHS1 was used for the diagnosis. Diffuse
mesangial hypercellularity with an increase in mesangial
matrix and focal dilatation of proximal tubules was ob-
served in all patients. At least four of the patients (pa-
tients 3–5 and 8) were from consanguineous families
(tables 1 and 2).
Southern Hybridization
DNA from 10 unrelated non-Finnish patients was di-
gested with EcoRI restriction enzyme and electropho-
resed in an agarose gel. DNA was blotted to a nitro-
cellulose filter, and the filter was hybridized with a
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Table 3
PCR Primer Sets for Amplifying Exons of NPHS1
Exon 5′ Primer 3′ Primer
Product Size
(bp)
5′ UTR gctgactctgccagtgcctg cagggccatcacaggtcccc 643
1–2 gagaaagccagacagacgcag agcttccgctggtggct 491
3–4 agccaccagcggaagct ctcccttcccactccagagg 530
5 cagaatctatcttgcggggag catggggaaaattaggggtcaag 187
6–7 tctccctgactccccaaatttc ctcaggactggctcccagac 544
8–9 gacagtggggtctgggagccagtcctgag gagtcatgccctcagcccc 623
10–11 cacgatggataggggtgctg cctggtccttcccccacatt 465
12–13 aacccagtgggcagggtagggg gacatgcgtggagggggcga 668
14 cctagtgcctctccagcc gagtagtttagggtcaagaagg 288
15–16 cctgatctccaatctgtccttg ccacaatgggcaaggttccttg 484
17 cacccagacctgtctgggcc gtccccactcccaaggaactc 257
18–19 gaggctacagaagggacaatttg gctggaggtccagacctggg 561
20 ggatggatgcatagatgattcc caatcagggatgtgggaatg 297
21–22 cctggacagaatcttctggaatt cctacacatcctctgaggaatac 487
23 gaggctgagaaatatttaaagcttat gagaccaggaggttccattct 188
24–26 ctcggggagacccacccc cctgatgctaacggcagggc 611
27–28 tgcccttccgggcacagtgg tacaagcaataggaggtaggc 438
29 cagatcttcaatgaagacctaca gagacagaatctcgctctg 747
radioactively labeled 1.3-kb nephrin cDNA probe (cor-
responding to exons 1–10).
Mutation Screening
Exons of the NPHS1 gene were amplified by PCR
(Perkin-Elmer Cetus 9600) with primers designed for
exons 1–29 (table 3), and the PCR products were se-
quenced in ABI 377 and ABI 310 sequencers (Perkin-
Elmer). PCR reactions were performed in a total volume
of 25 ml, which contained 20 ng of template DNA, 1#
AmpliTaq reaction buffer (Perkin-Elmer), 0.2 mM each
nucleotide, 100 ng of primers, and 0.5 U of AmpliTaq
Gold DNA polymerase (Perkin-Elmer). The reactions
were performed for 30 cycles, with denaturation at 95C
for 1 min, annealing at 60C for 1 min, and extension
at 72C for 1 min. In the first cycle, denaturation was
performed for 12 min, and in the last cycle, the extension
lasted for 8 min. Both strands of the PCR products were
then sequenced with dRhodamine and BigDye termi-
nator sequencer chemistries (Perkin-Elmer).
Results
Structure of the NPHS1 Gene
The structure of the NPHS1 gene was predicted from
the genomic sequence (cosmid clone R33502, Genbank
accession number AC002133) by several exon-predic-
tion programs. On the basis of these results, the coding
regions of the NPHS1 gene were amplified from fetal
kidney cDNA, and the exon-intron structure was deter-
mined by comparing the sequence of the 4.3-kb human
nephrin cDNA with the genomic sequence (Kestila¨ et al.
1998). The gene was shown to span ∼26 kb, proceeding
5′ to 3′ from the telomere toward the centromere of
chromosomal region 19q13.1. The gene contains 29 ex-
ons, with sizes ranging from 25 to 216 bp (fig. 1 and
table 4). With the exception of exon 23, which has an
unusual donor site starting with GC, the exons have the
conventional acceptor (AG) and donor sites (GT). The
exon-prediction program GENSCAN could correctly
predict all exons except exon 23. The codon for the
translation initiator methionine is in the first exon, and
the translation stops at TAA in exon 29.
Initial studies on the transcription start site revealed
a primer extension product starting 157 bp upstream of
the starting methionine (data not shown). The sequence
of part of the NPHS1 promoter area and 5′ UTR is
shown in figure 2. In this area, there is no TATA box,
but there are two putative GATA factor binding sites,
three NF-1 sites, and one AP2 consensus sequence.
Nephrin, the NPHS1 gene product, is a putative trans-
membrane receptor that contains eight immunoglobulin
C2-like motifs (Kestila¨ et al. 1998). The first exon codes
for the signal peptide, and exons 2–20 encode the region
containing the immunoglobulin motifs. Each immuno-
globulin motif is encoded by two exons, except motif
Ig2, which is encoded by three exons. Exons 22 and 23
code for a fibronectin type III–like domain, and exon
24 codes for the transmembrane domain. Exons 25–29
encode the putative cytosolic domain and the 3′ UTR.
Analysis of the NPHS1 Gene Region in NPHS1
Patients
Southern analysis of DNA from NPHS1 patients did
not reveal large genomic rearrangements. Consequently,
we searched for mutations by PCR amplification and
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Figure 1 Schematic structure of the human NPHS1 gene. Top, Exons are indicated by black rectangles; introns and flanking sequences
are indicated by rectangles with diagonal lines. The exons are numbered. Bottom, EcoRI (E) and BamHI (B) map of the gene and scale in
kilobases.
direct sequencing of all 29 exon regions. DNA from 35
European, North American, and North African patients
with suspected NPHS1 was analyzed. The mutations are
summarized in tables 1 and 2. In 23 patients, changes
were found in both alleles, and in 5 patients, changes
were found in only one allele. No mutations were found
in 7 patients, despite analysis of the promoter region
and all 29 exon regions. DNA samples from parents
were also studied to analyze the mode of inheritance: a
pattern of Mendelian inheritance was observed in all
cases (data not shown).
Patients 1–8 (tables 1 and 2) were homozygous for
their specific mutations. Three of the homozygous mu-
tations result in single amino acid substitutions (patients
1–3), one results in deletion of three residues and inser-
tion of a new residue (patient 4), and one results in a
truncated polypeptide chain due to introduction of a
premature stop codon (patient 5). One Swedish patient
(patient 6) was homozygous for the Finmajor mutation.
Two patients (patients 7 and 8) had a deletion (8 and 2
bp, respectively) in a GA repeat sequence of the pro-
moter region. Patient 9 was homozygous for one mu-
tation (P368S) and had another mutation (L376V) in
one allele. Patients 10–23 were heterozygotes for a va-
riety of mutations. Of interest, two patients (patients 18
and 21) had three nucleotide changes. Five patients (pa-
tients 24–28) had a mutation in only one allele. The
most common missense change was Glu117rLys, which
was found either homozygously or heterozygously in
nine patients (table 5); however, this variant was also
found heterozygously in 8 of 20 individuals not having
NPHS1 and homozygously in 3 controls. This confirms
that this is not a disease-causing mutation.
Deletions and Insertions
There were six patients (patients 6, 16, 18–20, and
27) with the Finmajor mutation (2-bp deletion), one (pa-
tient 13) with a two-base insertion, two (patients 13 and
24) with different single base deletions, and one (patient
11) with a single base insertion; all of these mutations
lead to frameshifts and truncated proteins (table 1). The
sizes of truncated proteins are shown in figure 3. Also,
one 3-bp deletion results in the loss of Thr172 (patient
17). One mutation with a deletion of eight bases and
insertion of two bases in exon 6 was also found (patient
4). This mutation results in the deletion of Thr205,
Pro206, and Arg207 and an insertion of isoleucine in
the same site within the Ig2 motif.
Splice-Site and Nonsense Mutations
Three patients (patients 12, 22, and 26) had an iden-
tical splice-site change in exon 18, and one (patient 10)
had a GrC substitution in the splice-site consensus se-
quence of intron 4, changing a conserved G at position
5, which is necessary for correct splicing (Senapathy
et al. 1990) (table 1). Three different single base non-
sense mutations leading to introduction of a translation
stop codon were also found (patients 5, 10, and 16).
Missense Mutations
The 23 missense mutations (62%) causing substitu-
tion of a single amino acid are summarized in figure 3
and table 2. These amino acid changes were scattered
throughout the nephrin polypeptide chain: 21 were in
the immunoglobulin motifs of the extracellular domain,
one was between immunoglobulin motifs, one was in
the transmembrane domain, and one was in the cytosolic
domain (fig. 3). Nine of the mutations involved either
the loss or introduction of a cysteine residue (i.e., mu-
tations that can either alter the secondary structure of
the protein or result in new intra- or interchain disulfide
bonds that affect the function of the protein). The other
mutations result mainly in changes in the charge or size
of the amino acid. Of interest, one patient (patient 21)
had three different amino acid changes in heterozygous
forms (table 2). Each of them was an amino acid sub-
stitution to a cysteine residue. In this patient, two of the
changes were in the immunoglobulin domains (maternal
Table 4
Exon-Intron Boundaries and Sizes of Exons and Introns in the Human NPHS1 Gene
Exon Exon/Intron Boundaries Exon Size Intron Size
1 5′ UTR ATG GCC CTG... ...ACT GAA G gtgagtggga 5′ UTR  78 87
M A L T E G
2 gtgtcctcag GC CTG GCG... ...GCT AGA G gtaagggatc 216 71
L Q A R G
3 ccccctgcag GT GAA TTC... ...ATC CTG G gtatgggtgag 124 172
E F I L V
4 ctctcaccag TT CCT CCC... ...CTC CTG A gtgagtgtgg 129 515
P P L L S
5 ctgccccaag GT GGA CAG... ...ACA GCC AG gtgtggaaac 82 710
G Q T A R
6 ctcatcccag G GTG ACA... ...GTT CTG T gtgaggcagt 104 186
V T G K
7 tatcccccag TC CCT CCA... ...TGG CTG AAG gtgagggcaa 128 87
P P W L K
8 ctgtctccag AAT GGC CAG... ...GTC ACC T gtgagtcctg 173 181
N G Q V T F
9 gtccctgcag TT CCC CCT... ...GTC ATG GAT gtgaggcggg 158 239
P P V M D
10 tccctgccag GGA CTG CAT... ...GTA AAA T gtgagcccct 145 87
G L H V K Y
11 tccccgccag AT CCC GCC... ...TGG TAC AAG gttggtgcca 125 1,846
P A W Y K
12 cggcccgtag GAC TCG CGC... ...GTG CAG T gtgagggctc 187 209
D S R V Q F
13 cgtctcccag TT CCC CCA... ...GGG GAG AG gtgggagtgc 136 128
P P G E R
14 ggttccacag G CTG GAG... ...GTA CTG T gtatgtgccc 173 908
L E V L Y
15 ccctctgaag AC CGT CCA... ...AGT CCA G gtgagggaag 141 75
R P S P A
16 ccttccccag CG GGC GGC... ...GTG CAC T gtgagccccg 141 509
G G V H Y
17 cttccaccag AT GCT CCC... ...GAG AGA CTG gtgaggatcc 122 921
A P E R L
18 gggcctccag GGA GAA GAT... ...GTC AGA T gtgggtatta 172 98
G E D V R F
19 cccctcccag TT GCC CCC... ...GAT CCC AG gtgagcccaa 157 257
A P D P R
20 ttctctctag G TAC ACG... ...AGC ATC A gtatggaggg 152 2,108
Y T S I S
21 ctccccatag GC CGC CCT... ...TGC ATC AG gtgggtcctt 112 77
R P C I R
22 tgtcctgcag G TAT GAG... ...ACC CCA G gtgggaaggga 182 3,476
Y E T P G
23 caccccccag GT CTC CAC... ...CCT TCA G gcaagtcctca 57 3,942
L H P S G
24 ccacccctag GA CCC TCG... ...GCT GAG G gtgaggagaga 120 142
P S A E G
25 tttccttcag GC ATC TCA... ...GAG GCA GG gtaagtgggga 25 104
I S E A G
26 atcctggaag G TCG GAA... ...AGC TCC ACG gtaagtggggg 76 149
S E S S T
27 tggggaacag GTC AGC ACA... ...TCC CGA G gtgagttagga 94 96
V S T S R G
28 ccaactccag GT TTC ACA... ...GTG CAG ATG gtgagaagctt 113 4,198
F T V Q M
29 tgcctgtcag GGA CCC TGG... ...CAT CTG GTG taa 3′ UTR 129  3′ UTR
G P W H L V ∗
NOTE.—Intron sequences are shown in lowercase letters. Exon sequences are shown in uppercase letters, with the
amino acid residues shown below (one-letter codes). The translation stop codon taa is indicated by an asterisk (∗).
Exon and intron sizes given are in base pairs.
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Figure 2 Sequence of the immediate upstream region and 5′ end
of the NPHS1 gene. The putative 5′ end of the transcript is shown
with uppercase letters. A star indicates the transcription initiation site
as detected by primer extension. The consensus sequences for tran-
scription factors GATA-1, GATA-2, NF-1, and AP-2 are boxed. The
ATG codon for the initiator methionine is indicated by boldface type,
and the GA-rich region containing a mutation in two patients (see
text) is underlined. The nucleotides are numbered so that the first
nucleotide of the codon for the initiator methionine is 1.
and paternal inheritance, respectively), and one was in
the cytosolic domain (maternal inheritance) of nephrin.
Sequence Variants in Control Individuals
All together, 23 sequence variants resulting in amino
acid substitutions in the nephrin polypeptide chain were
found in NPHS1 patients. To examine whether these
variants are normal polymorphisms or disease-causing
mutations, we sequenced corresponding codons from the
DNA of 30 unrelated non-Finnish individuals. These
analyses revealed three sequence variants, of which two
were found as a homozygous change in controls (table
5). The most frequent sequence variant (in 22/60 ana-
lyzed chromosomes) leads to a Glu117rLys change in
the Ig1 motif. This was found as a homozygous change
in five control subjects and is therefore most likely a
common polymorphism. Also, a sequence change lead-
ing to the amino acid change Asn1077rSer in exon 24
was observed in both alleles of one Finnish control. This
mutation was also present as a heterozygous change in
five NPHS1 patients (patients 17, 18, 19, 27, and 28).
This change was observed to be inherited together with
the Finmajor mutation. Four control subjects were heter-
ozygotes for a mutation in exon 10 leading to an
Arg408rGln change found in three compound hetero-
zygous patients (patients 18, 23, and 28) (table 2). Pa-
tient 18 also had two other mutations, Finmajor and
Cys465Tyr.
Discussion
The present study provides the complete structure of
the human nephrin gene (NPHS1) as well as information
on sequences and PCR conditions facilitating mutation
analysis of all 29 exons of the gene in individuals with
NPHS1. Furthermore, we have identified a large number
of novel biallelic mutations in the gene in NPHS1 pa-
tients, demonstrating the involvement of this gene in the
disease. Surprisingly, several sequence variants were also
detected in control individuals, indicating that this gene
is quite susceptible to mutagenesis.
Except for exon 23, the 29 exons of the gene were
shown to have conventional acceptor (AG) and donor
(GT) sites; exon 23, which encodes part of the type III
fibronectin domain, has a donor site starting with GC
instead of GT. Sequencing of DNA from several indi-
viduals showed that this sequence is a normal feature of
the gene. Although extremely rare, this donor site se-
quence has been described for a single exon in a few
genes from different species (Shapiro and Senapathy
1987; Soininen et al. 1989; Senapathy et al. 1990). The
potential significance of this donor site sequence is still
unknown. Each of the immunoglobulin motifs of ne-
phrin was shown here to be encoded by two exons,
except for Ig2, which is encoded by three exons. Thus,
the nephrin gene resembles the genes for a group of
transmembrane cell adhesion proteins belonging to the
immunoglobulin superfamily, such as the neural cell ad-
hesion molecules N-CAM (Owens et al. 1987) and
MUC18 (Sers et al. 1993), in which each immunoglob-
ulin motif is encoded by two exons. In several other
genes coding for proteins of the immunoglobulin su-
perfamily, each immunoglobulin motif is encoded by a
single exon (see Lawlor et al. 1990; Schrewe et al. 1990;
Cybulsky et al. 1991; Nakano et al. 1991).
In this study, we identified 32 novel mutations in the
NPHS1 gene of Finnish and non-Finnish patients, mak-
ing the number of known mutations in this gene 36. In
addition, two common polymorphisms (Glu117rLys
and Asn1077rSer) were found. We have done mutation
analysis for 79 individuals with suspected NPHS1 and
found mutations in both alleles of NPHS1 in 67 patients
and in only one allele in 5 patients, by sequencing all
exon regions and the immediate promoter, where two
sequence changes were detected. This corresponds to a
mutation detection rate of ∼88% by the PCR amplifi-
cation and direct DNA sequencing approach. It is pos-
sible that the few mutations yet to be identified in pa-
tients in our study are located in gene regions containing
important regulatory elements of the NPHS1 gene.
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Table 5
Sequence Variants in the NPHS1 Gene in Control Individuals
Nucleotide
Change Exon
Effect on
Coding Sequence
Heterozygote or
Homozygote
No. of Control
Subjects
(n  30)
nt349(GrA)a 3 Glu117rLys Heterozygote 12
Homozygote 5
nt3230(ArGb 24 Asn1077rSer Homozygote 1
nt1223 (GrA)c 10 Arg408rGln Heterozygote 4
a Present also as a homozygous change in three NPHS1 patients (patient 9; table
2) and as heterozygous change in six NPHS1 patients (patients 11, 13, 15, 16, 24,
and 28; tables 1 and 2). Also found in fetal kidney cDNA library.
b Present also as a heterozygous change in five NPHS1 patients (patients 17, 18,
19, 27, and 28; tables 1 and 2).
c Present also as a heterozygous change in three NPHS1 patients (patients 18,
23, and 28; tables 1 and 2).
Although NPHS1 has been reported mainly in the ho-
mogeneous Finnish population (Norio et al. 1966), it is
also present elsewhere (Mauch et al. 1994), and the pre-
sent study suggests that mutations in the nephrin gene
are a general cause of hereditary CNF. We have previ-
ously reported the presence of two main mutations, Fin-
major and Finminor, in 94% of 98 known Finnish NPHS1
chromosomes (Kestila¨ et al. 1998). The present study
reveals that these two mutations are rare in other pop-
ulations. These mutations were found to be homozygous
or compound heterozygous in 44 of 49 Finnish patients
studied, 4 being heterozygotes, with the second mutation
unknown. In the present study, we identified four novel
mutations in Finnish patients; thus, we have now found
mutations in all but two of the analyzed Finnish NPHS1
chromosomes. A total of 34 novel sequence variants
were identified in 36 non-Finnish and Finnish patients
with suspected NPHS1.
Mutations found in the promoter region of one North
American and one North African patient (patients 7 and
8) are interesting. Patient 7, with a (GA)4 deletion, did
not have a typical course of NPHS1. She presented with
proteinuria and mild edema at 4 mo of age. A kidney
biopsy revealed mesangial proliferation without sclero-
sis. The nephrotic syndrome did not respond to steroid
therapy. The child’s edema was controlled with oral di-
uretics; albumin infusions were never required. Her renal
function deteriorated gradually until age 5 years, when
she received a kidney transplant. There has been no re-
currence of nephrotic syndrome during 12 years of fol-
low-up. This case indicated that NPHS1 might be in-
volved in a broader spectrum of disease than the classic
Finnish type of NPHS1. However, in patient 8, who had
the classical severe NPHS1 phenotype, there was only a
deletion of GA in the same GA repeat sequence. Whether
these sequence changes in the promoter actually cause
disease remains to be shown.
The results of this study are of significant importance
for the diagnosis of CNF. In the absence of DNA-based
diagnostic methods, measurements of a-fetoprotein lev-
els in the amniotic fluid or maternal blood have been
used for prenatal diagnosis and abortions of NPHS1
fetuses in families at risk (Seppa¨la¨ et al. 1976). In some
cases, diagnosis of fetal NPHS1 has been made on the
basis of increased a-fetoprotein levels during pregnancy,
without a known family history for the disease. How-
ever, since elevation of a-fetoprotein levels is not specific
for the CNF, DNA-based diagnosis should now be the
preferred approach (Ma¨nnikko¨ et al. 1997). Although
the diagnostic procedure described in this study does not
reveal 100% of the mutations causing CNF, most of the
mutations can now be identified, especially in Finnish
families (Kestila¨ et al. 1998; present study).
The large number of mutations described here can
shed light on the nature of nephrin, the product of
NPHS1. Small deletions and insertions, splice-site mu-
tations, and some of the nonsense mutations in the gene
result in frameshifts, premature stop codons, or abnor-
mal mRNA splicing, resulting in nonfunctional protein.
Since most of the truncated nephrin molecules lack the
intracellular and transmembrane domains, they reveal
only limited information on active domains of nephrin.
In contrast, comparing missense mutations that lead to
disease with those resulting in neutral amino acid sub-
stitutions can reveal significant information about func-
tionally important domains and amino acid residues. Of
the 36 mutations now known, 21 are missense mutations
that result in amino acid substitutions. As shown in fig-
ure 3, most of the mutations causing amino acid sub-
stitutions are located in the extracellular domain of ne-
phrin, one being in the transmembrane domain and one
in the cytosolic domain. With the exception of mutation
Ser724rCys, which probably leads to the introduction
of abnormal intrachain or interchain disulfide bonds, the
mutations in the extracellular domain are within the
IgC2-like motifs, indicating that these motifs are func-
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Figure 3 Top, Location of missense mutations and polymorphisms in the nephrin polypeptide chain. Locations of cysteines are indicated
with blackened dots. Middle, Scale in amino acid residues. Bottom, Sizes of truncated nephrin proteins of NPHS1 patients. Sequence out of
frame is shown with unblackened bars. The patient numbers (table 1) are shown on the right. Sp  signal peptide; Ig  immunoglobulin motif;
Fn  fibronectin type III motif; and Tm  transmembrane domain.
tionally important and that their function is critically
dependent on certain amino acid residues. Some clus-
tering of mutations was observed. For example, about
half of the amino acid changes occurred in motifs Ig4
(six mutations) and Ig7 (five mutations). One mutation
was found in Ig3, and two each were found in Ig1, Ig2,
Ig5, and Ig6, but no amino acid substitutions were ob-
served in Ig8.
Future studies may reveal whether the clustering of
mutations observed here reflects functional importance
of the amino acid residues and motifs involved or is just
the result of small sample size. Some of the amino acid
substitutions were found heterozygously in a few of the
control subjects. It is not clear whether these changes
affect the function of the nephrin protein, but since the
same amino acid changes were also present in patients
with no other mutations found, we cannot exclude that
these mutations actually cause disease. However,
whether an amino change is a rare polymorphism or
whether it causes disease will not be resolved until a
functional assay is devised.
In conclusion, the results of this study clearly dem-
onstrate the involvement of the nephrin gene in NPHS1.
Whatever its function, the nephrin protein must be cru-
cial for the selective filtration function of the kidney,
because the consequence of nephrin absence or mal-
function is massive proteinuria. The study also indicates
that mutations in nephrin may be involved in proteinuric
patients who do not exhibit the classic severe Finnish
type of CNF. Consequently, there is a reason to examine
60 Am. J. Hum. Genet. 64:51–61, 1999
the involvement of nephrin in both genetic and acquired
kidney disorders in which proteinuria is displayed.
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